Relay Therapeutics
RLAY
161 hedge funds and large institutions have $2.76B invested in Relay Therapeutics in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 69 increasing their positions, 30 reducing their positions, and 18 closing their positions.
304% more call options, than puts
Call options by funds: $7.22M | Put options by funds: $1.78M
130% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 30
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
37% more capital invested
Capital invested by funds: $2.02B → $2.76B (+$742M)
9% more funds holding
Funds holding: 148 → 161 (+13)
8.22% less ownership
Funds ownership: 110.99% → 102.77% (-8.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.7M |
| 2 |
AG
Artal Group
Luxembourg
|
+$16.6M |
| 3 |
CC
Casdin Capital
New York
|
+$13.5M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$13.2M |
| 5 |
Goldman Sachs
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$24.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.2M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$11M |
RLAY Hedge Fund Activity: Q3 2022 in Review
161 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2022, worth a combined $2.76B — up 37% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RLAY positions and 18 closed out — a net gain of 13 holders — while 69 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27.7M. The largest seller was Wellington Management Group, cutting an estimated $30.5M.
- 161 institutional investors held Relay Therapeutics (RLAY) as of Q3 2022, up from 148 in Q2 2022.
- Funds reported $2.76B of Relay Therapeutics stock for Q3 2022, up 37% quarter-over-quarter.
- 31 funds opened new Relay Therapeutics positions in Q3 2022 and 18 closed out, a net change of +13 holders.
- The largest Relay Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $27.7M added.
- The largest Relay Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $30.5M sold.
Based on aggregated 13F filings for Q3 2022.